SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/22/14 Adhera Therapeutics, Inc. 10-K 12/31/12 74:8.2M Toppan Vite NY Inc./FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 825K 2: EX-10.43 Material Contract HTML 43K 3: EX-10.51 Material Contract HTML 63K 4: EX-21.1 Subsidiaries List HTML 21K 5: EX-23.1 Consent of Experts or Counsel HTML 21K 6: EX-31.1 Certification -- §302 - SOA'02 HTML 25K 7: EX-32.1 Certification -- §906 - SOA'02 HTML 22K 52: R1 Document and Entity Information HTML 52K 42: R2 Consolidated Balance Sheets HTML 115K 50: R3 Consolidated Balance Sheets (Parentheticals) HTML 44K 54: R4 Consolidated Statements of Operations HTML 77K 69: R5 Consolidated Statements of Stockholders' Equity HTML 89K (Deficit) 44: R6 Consolidated Statements of Cash Flows HTML 134K 49: R7 Business, Liquidity and Summary of Significant HTML 161K Accounting Policies 38: R8 Loss on impairment of intangible assets HTML 36K 28: R9 Property and Equipment HTML 36K 70: R10 Restructuring Charges HTML 37K 56: R11 Notes Payable HTML 29K 55: R12 Stockholders' Equity HTML 78K 60: R13 Stock Incentive Plans HTML 107K 61: R14 Employee Benefit Plan HTML 24K 59: R15 Income Taxes HTML 44K 62: R16 Intellectual Property and Collaborative Agreements HTML 39K 51: R17 Commitments and Contingencies HTML 27K 53: R18 Subsequent Events HTML 23K 58: R19 Business, Liquidity and Summary of Significant HTML 197K Accounting Policies (Policy) 74: R20 Business, Liquidity and Summary of Significant HTML 130K Accounting Policies (Tables) 65: R21 Property and Equipment (Tables) HTML 34K 46: R22 Restructuring Charges (Tables) HTML 32K 57: R23 Stockholders' Equity (Tables) HTML 56K 48: R24 Stock Incentive Plans (Tables) HTML 107K 22: R25 Income Taxes (Tables) HTML 37K 66: R26 Business, Liquidity and Summary of Significant HTML 37K Accounting Policies (Details) 71: R27 Business, Liquidity and Summary of Significant HTML 34K Accounting Policies (Details 1) 32: R28 Business, Liquidity and Summary of Significant HTML 104K Accounting Policies (Details 2) 31: R29 Business, Liquidity and Summary of Significant HTML 61K Accounting Policies (Details 3) 36: R30 Business, Liquidity and Summary of Significant HTML 31K Accounting Policies (Details 4) 37: R31 Business, Liquidity and Summary of Significant HTML 29K Accounting Policies (Details 5) 39: R32 Business, Liquidity and Summary of Significant HTML 68K Accounting Policies (Detail Textuals) 20: R33 Loss on impairment of intangible assets (Detail HTML 31K Textuals) 63: R34 Loss on impairment of intangible assets (Detail HTML 39K Textuals 1) 45: R35 Property and Equipment (Details) HTML 34K 47: R36 Property and Equipment (Detail Textuals) HTML 22K 25: R37 Restructuring Charges (Details) HTML 28K 73: R38 Restructuring Charges (Detail Textuals) HTML 52K 14: R39 Notes Payable (Detail Textuals) HTML 36K 40: R40 Notes Payable (Detail Textuals 1) HTML 53K 68: R41 Stockholders' Equity (Details) HTML 42K 24: R42 Stockholders' Equity (Details 1) HTML 38K 30: R43 Stockholders' Equity (Preferred Stock) (Details) HTML 45K 34: R44 Stockholders' Equity (Common Stock) (Details) HTML 154K 43: R45 Stockholders' Equity (Warrants) (Details) HTML 68K 19: R46 Stockholders' Equity (Subscription Investment HTML 27K Units) (Details) 27: R47 Stock Incentive Plans (Stock-Based Compensation HTML 27K Expense) (Details) 16: R48 Stock Incentive Plans (Stock Option Activity) HTML 44K (Details) 67: R49 Stock Incentive Plans (Stock options outstanding ) HTML 47K (Details) 23: R50 Stock Incentive Plans (Weighted Average HTML 29K Assumptions) (Details) 64: R51 Stock Incentive Plans (Detail Textuals) HTML 73K 26: R52 Employee Benefit Plan (Detail Textuals) HTML 22K 41: R53 Income Taxes (Details) HTML 47K 15: R54 Income Taxes (Detail Textuals) HTML 33K 18: R55 Intellectual Property and Collaborative Agreements HTML 45K (Detail Textuals) 33: R56 Intellectual Property and Collaborative Agreements HTML 73K (Detail Textuals 1) 21: R57 Commitments and Contingencies (Details) HTML 33K 72: XML IDEA XML File -- Filing Summary XML 112K 17: EXCEL IDEA Workbook of Financial Reports XLSX 188K 29: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 1.13M 8: EX-101.INS XBRL Instance -- mrna-20121231 XML 1.66M 10: EX-101.CAL XBRL Calculations -- mrna-20121231_cal XML 130K 11: EX-101.DEF XBRL Definitions -- mrna-20121231_def XML 676K 12: EX-101.LAB XBRL Labels -- mrna-20121231_lab XML 1.43M 13: EX-101.PRE XBRL Presentations -- mrna-20121231_pre XML 1.01M 9: EX-101.SCH XBRL Schema -- mrna-20121231 XSD 243K 35: ZIP XBRL Zipped Folder -- 0001571049-14-003110-xbrl Zip 171K
Exhibit 21.1
List of Subsidiaries
Name | State of Incorporation | Ownership | ||||||
Cequent Pharmaceuticals, Inc. | Delaware | 100 | % | |||||
MDRNA Research, Inc. | Delaware | 100 | % | |||||
Atossa HealthCare, Inc. | Delaware | 100 | % |
C: